Wolverine Legal Status, FDA 503A Category, and Compounding Access

The Present-Tense FDA Status

Wolverine legal status begins with a single present-tense fact: both of the blend's constituents are FDA 503A Category 2 bulk drug substances. BPC-157 (BPC-157 (free base) / BPC-157 acetate) and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" were each identified by the FDA as bulk drug substances that may present significant safety risks and placed in Category 2 for 503A compounding, effective with the September 29, 2023 update to the agency's list of nominated substances ^[15][16].

Under the FDA's interim policy, Category 2 substances are those nominated with sufficient information for the FDA to evaluate but identified as raising significant safety risks; they are not covered by the enforcement-discretion policy that applies to Category 1, and the FDA has stated it would consider taking action against a compounder for compounding with a Category 2 substance ^[17]. The agency's cited safety rationale for both entries includes potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization ^[15][16]. Neither BPC-157 nor the TB-500 fragment is an FDA-approved drug, and the blend has no approved therapeutic indication.

FDA approval of a finished drug is a separate question from whether a bulk substance may be used in compounding; none of these substances is an FDA-approved drug ^[17].

What Is Under Active FDA Review

Access to compounded peptides is under active FDA review, and the picture may change. Both constituents are on the published agenda of the Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026 — BPC-157 (free base) / BPC-157 acetate and TB-500 (free base) / TB-500 acetate are each listed as substances "being considered for inclusion on the 503A Bulks List" ^[18].

That is a scheduled evaluation and discussion, not a listing decision and not a change in current status. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by the advisory committee; being discussed by the committee is a step in evaluation, not a final listing decision ^[17]. A committee discussion is advisory, and no outcome should be assumed ^[18]. As of the date this reference was compiled, the last FDA action confirmable from FDA.gov for both substances is the Category 2 placement above — so that is what this page states. The July 2026 meeting is noted here only as a scheduled discussion of substances under evaluation.

BPC-157 and Compounding Pharmacy Access

Can you get BPC-157 from a compounding pharmacy?

BPC-157 is in FDA 503A Category 2, identified as raising significant safety risks and not within the FDA's enforcement-discretion policy for 503A compounding, effective with the September 29, 2023 update ^[15]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the FDA's 503A bulks list; substances the FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands ^[17].

This is the general framework for compounding pharmacy access, and it applies to the TB-500 fragment identically. In broad terms, a legally compounded medication in the United States is prepared only after an individual patient is evaluated by an appropriately licensed prescriber — in person or via a compliant telehealth encounter — who determines a compounded preparation is appropriate and issues a valid, patient-specific prescription; the preparation is then made by a state-licensed 503A compounding pharmacy or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility ^[17]. Telehealth is one front-end channel for the prescriber-evaluation step; it does not change which substances are eligible to be compounded or remove the need for a legitimate clinical evaluation and a valid prescription ^[17].

The ingredient-eligibility caveat is decisive: the compounder may use the requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules, and an ingredient the FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands ^[17]. This page names no pharmacy, clinic, telehealth provider, or vendor, and it describes no human dose.

FDA 503A Status of the Blend

What is the FDA 503A status of Wolverine?

The blend as such has no separate FDA classification. It inherits the status of its two constituents, each of which is an FDA 503A Category 2 bulk drug substance — identified as presenting significant safety risks and not covered by the enforcement-discretion policy for 503A compounding — effective with the September 29, 2023 update ^[15][16].

Is the Wolverine blend legal?

There is no approved "Wolverine" product. Section 503A governs traditional, patient-specific compounding by state-licensed pharmacies and physicians; 503B governs FDA-registered outsourcing facilities ^[17]. A compounded preparation may lawfully be made only when its active ingredient is permitted under that framework, and both of the blend's constituents are currently in Category 2 — outside FDA enforcement discretion for compounding ^[15][16]. This is the Wolverine legal status and FDA 503A category in summary: two unapproved constituents, both Category 2, with the access framework described above. This is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply any substance.